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Synthetic glucocorticoids (GC) are the mainstay therapy for treatment of acute and 
chronic inflammatory disorders. Due to the high adverse effects associated with long-
term use, GC pharmacology has focused since the nineties on more selective GC 
ligand-binding strategies, classified as selective glucocorticoid receptor (GR) agonists 
(SEGRAs) or selective glucocorticoid receptor modulators (SEGRMs). In the current 
study, GSK866 analogs with electrophilic covalent-binding warheads were developed 
with potential SEGRA properties to improve their clinical safety profile for long-lasting 
topical skin disease applications. Since the off-rate of a covalently binding drug is 
negligible compared to that of a non-covalent drug, its therapeutic effects can be pro-
longed and typically, smaller doses of the drug are necessary to reach the same level of 
therapeutic efficacy, thereby potentially reducing systemic side effects. Different ana-
logs of SEGRA GSK866 coupled to cysteine reactive warheads were characterized for 
GR potency and selectivity in various biochemical and cellular assays. GR- and NFκB-
dependent reporter gene studies show favorable anti-inflammatory properties with 
reduced GR transactivation of two non-steroidal GSK866 analogs UAMC-1217 and 
UAMC-1218, whereas UAMC-1158 and UAMC-1159 compounds failed to modulate 
cellular GR activity. These results were further supported by GR immuno-localization 
and S211 phospho-GR western analysis, illustrating significant GR phosphoactivation 
and nuclear translocation upon treatment of GSK866, UAMC-1217, or UAMC-1218, 
but not in case of UAMC-1158 or UAMC-1159. Furthermore, mass spectrometry 
analysis of tryptic peptides of recombinant GR ligand-binding domain (LBD) bound 
to UAMC-1217 or UAMC-1218 confirmed covalent cysteine-dependent GR binding. 
Finally, molecular dynamics simulations, as well as glucocorticoid receptor ligand- 
binding domain (GR-LBD) coregulator interaction profiling of the GR-LBD bound 
to GSK866 or its covalently binding analogs UAMC-1217 or UAMC-1218 revealed 
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subtle conformational differences that might underlie their SEGRA properties. 
Altogether, GSK866 analogs UAMC-1217 and UAMC-1218 hold promise as a novel 
class of covalent-binding SEGRA ligands for the treatment of topical inflammatory skin 
disorders.
Keywords: glucocorticoid receptor, segra, nFkB, electrophilic, covalent warhead, cysteine
inTrODUcTiOn
Synthetic glucocorticoids (GCs) such as prednisolone, dexa-
methasone, or fluticasone esters remain the frontline treatment 
for (chronic) inflammatory disorders, autoimmune diseases, 
and/or hematological malignancies (1). Therapeutic activities 
of synthetic GCs are mediated by the glucocorticoid hormone 
receptor (GR) belonging to a superfamily of ligand-inducible 
transcription factors. In the absence of GCs, the GR resides in 
the cytosol in an inactive state complexed with heat shock pro-
teins (HSPs) and immunophilins (2). Binding of GCs to the GR 
activates and then translocates to the nucleus by causing a con-
formational change in the GR followed by a dissociation of the 
bound HSPs. The activated GR can then regulate gene activation 
by GR dimerization (transactivation) and binding to glucocorti-
coid response elements (GREs) in the genome, or regulate gene 
repression by GR monomers (transrepression) which interfere 
with the activity of pro-inflammatory transcription factors, such 
as NFκB and AP1 (3, 4). Unfortunately, major metabolic side 
effects, such as glucose intolerance, muscle wasting, skin thin-
ning (atrophy), and osteoporosis, severely limit their prolonged 
therapeutic use (5). Studies in animal models have shown that 
the GC-mediated side effects, such as diabetogenic activity, 
osteoporosis, and skin atrophy, are mainly due to the activation 
of the transactivation pathway (6, 7). Hence, a selective GC that 
is able to repress inflammation without transactivation should 
preserve many of the desirable therapeutic anti-inflammatory 
effects, while minimizing undesired side effects (8–11). This 
was also demonstrated by the introducing a point mutation in 
the GRdim mice that prevented GR from dimerizing and binding 
to DNA, thereby blocking transactivation without interfering 
with anti-inflammatory transrepression effects (12). Therefore, 
new GC pharmacological approaches are being developed that 
attempt to amplify the therapeutic beneficial anti-inflammatory 
(transrepression) actions and to minimize adverse metabolic 
(transactivation) activities. These compounds are classified as 
selective glucocorticoid receptor agonists (SEGRAs) or selec-
tive glucocorticoid receptor modulators (SEGRMs) (7, 13, 14). 
Various crystal structures of nuclear hormone receptor binding 
domains co-crystallized with different ligands demonstrate 
subtle conformational changes of the GR ligand-binding domain 
(LBD) which result in variable agonistic/antagonistic or mixed 
pharmacological properties depending on specific coactivator or 
corepressor interactions (14–17). Since the late 1990s, this has 
triggered researchers to synthetize various SEGRA and SEGRM 
compounds, with GSK866 and mapracorat being the prototypes 
of this non-steroidal class of compounds, in which bulky, bicyclic 
aromatic substituents account for the structural similarity to 
corticoids (7, 13–15, 18–20). In vivo efficacy for SEGRA/SEGRM 
compounds with reduced side effects has already been demon-
strated for treatment of acute infections, such as rheumatoid 
arthritis, asthma, and colitis, in the clinic (20–22).
In the current study, GSK866 analogs with electrophilic war-
heads were evaluated for potential SEGRA properties to improve 
their clinical safety profile for long-lasting topical skin disease 
applications (14). Of particular interest, reduced GR transactiva-
tion was observed for GR, covalently bound to dexamethasone-
21-mesylate (23, 24). This proof-of-concept study builds further 
upon the ideas that emerged from the recent development of 
covalent-binding kinase inhibitors (25–28), with the underlying 
idea to develop long-lasting GR agonists with applicability in 
the anti-inflammatory domain. Furthermore, evidence suggests 
that there is a reduced risk for the development of resistance 
against covalent drugs, which is a major challenge in areas 
such as oncology and infectious disease (28, 29). When drugs 
bind their target covalently, the off-rate is negligible compared 
to that of a non-covalent drug and, therefore, such covalently 
binding drugs should have a prolonged therapeutic effect in vivo. 
Another advantage of the irreversible binding is that smaller 
doses of the drug are necessary to obtain therapeutic efficacy and 
systemic side effects can be reduced. Covalent cysteine binding 
drugs have gained renewed interest, since the Food and Drug 
Administration (FDA) awarded a “breakthrough drug” status to 
cysteine-directed covalent inhibitors that target Bruton’s tyros-
ine kinase (BTK) and a drug-resistant EGFR mutant in cancer 
(26, 28–30). In addition, most widely prescribed cancer drugs, 
such as the proteasome inhibitor bortezomib, CYP17 inhibitor 
abiraterone acetate and P6H5 enzyme (Cyclooxygenase) inhibi-
tor widely known as aspirin, were also found to bind their targets 
covalently (31–33). However, possible therapeutic applications 
for potential covalent-binding SEGRAs remain to be explored.
In the current study, we performed structure function analysis 
of different GSK866 analogs with cysteine reactive warheads to 
evaluate potential SEGRA properties by different biochemical 
and cellular assays, including (reporter) gene expression analysis, 
immuno-localization studies, proteomic GR binding studies, 
glucocorticoid receptor (GR)-coregulator interaction profiling, 
and molecular dynamic simulation.
MaTerials anD MeThODs
cell culture and Materials
TNF-sensitive L929sA fibrosarcoma cells have previously been 
characterized in our lab (34–36). A549 adenocarcinoma human 
alveolar basal epithelial cells were a kind gift from Dr. Ian Adcock 
and have previously been described (35–37). Fibrosarcoma and 
adenocarcinoma cells were grown in Dulbecco’s modified Eagle 
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medium (DMEM, Invitrogen) with 10% fetal calf serum (FCS, 
PAA) 100 U/ml penicillin and 100 mg/ml streptomycin (PAA). 
Stable transfected NFκB-luc and GRE-luc reporter gene cell 
lines have been described previously (8, 38). HaCat keratinocyte 
cells were purchased from the ATCC (American Type Culture 
Collection, USA) and kept in DMEM high glucose (Invitrogen) 
with 10% FCS, 100 U/ml penicillin, and 100 mg/ml streptomycin. 
Typically, cells were seeded at a density of 30,000 cells/cm2 1 day 
before the experiment. Synthesis of Dex-mesylate (Dex-Mes) 
and SEGRA GSK866 analogs UAMC-1158, -1159, -1217, and 
-1218 has been previously described (14). Dexamethasone and 
RU486 were purchased from SIGMA-Aldrich. All compounds 
were routinely dissolved in DMSO at a concentration of 10–2 M. 
For cell culture and other experiments, compounds were further 
diluted to their final concentration in DMEM media without 
antibiotics and serum. For experiments, the cells were seeded on 
multi-well dishes and allowed to attach for 24 h. Prior to treat-
ment with University of Antwerp Medicinal Chemistry (UAMC) 
compounds or Dex stimulation, cells were cultured in low FCS 
(<2%) for about 12 h.
immunolocalization studies
To detect endogenous GR in A549 cells, cells were grown in 
serum free media for 24 h followed by treatment with 1 µM of 
specific GR ligands. After 30 min of treatment, cells on the cover 
glass were fixed in 4% formaldehyde in phosphate-buffered 
saline (PBS), permeabilized with 0.3% Triton X-100–PBS, and 
then blocked in 5% milk, 10% FCS, 0.3% bovine serum albumin, 
and 0.3% Triton X-100 in PBS for 30 min at room temperature. 
Primary antibodies against anti GR-antibody (SantaCruz 
Biotechnology) were used at a dilution of 1:200. Nuclei were 
stained by DAPI and samples were analyzed using a confocal 
Leica LSM410 microscope. To quantify nuclear translocation of 
GR in a standardized manner, multichannel fluorescence images 
were analyzed using a script for FIJI image analysis freeware 
(http://fiji.sc) that is essentially based on a pipeline described 
before (CellBlocks.ijm) (39), and is available upon request. In 
brief, the analysis first segments nuclei in the Hoechst/DAPI 
channel and then uses the nuclear mask to define perinuclear 
cytoplasmic regions of interest (ROIs). Nuclei are detected 
after local contrast enhancement and Gaussian smoothing to, 
respectively, cover for spatial illumination heterogeneity and 
noise. After automatic thresholding (Isodata algorithm), touch-
ing nuclei are separated using a conditional watershed algorithm 
(40). Next, cytoplasmic ROIs are determined as concentric 
bands around the nuclei by Voronoi-restrained region growing 
(41). Finally, the average intensity of the GR channel is measured 
in both the nuclear and cytoplasmic ROIs and the nuclear-to 
cytoplasm signal intensity ratio (N/C Ratio) is calculated per cell 
(Figure S1 in Supplementary Material) (42).
cell-Based reporter assays
In order to compare transactivation and transrepression poten-
cies of the different synthesized GSK866 analogs, we performed 
GRE- and NFκB-luciferase-dependent reporter gene studies in 
stable transfected cell lines, as previously described (3, 8). HaCat 
cells expressing p(GRE)2 50-Luc and L929sA cells expressing 
p(GRE)250-Luc or p(NFκB)350-Luc were cultured in DMEM 
medium with 1% l-glutamine, supplemented with 10% feral 
bovine serum (FBS), 100 µg/ml streptomycin, and 100 IU/mL 
penicillin in a humidified 5% CO2 atmosphere. Cells were 
passaged every 2 days at a dilution of 1:6. Reporter gene cells 
were plated at a density of 0.5 × 105 cells/well in 24 well plates 
and grown overnight. p(GRE)250-Luc-dependent reporter gene 
cells were treated with solvent (DMSO) or compound (100 fM, 
1 nM, 10 nM, 100 nM, and 1 µM) for 6 h, whereas in case of 
p(NFκB)350-Luc, TNF (2,500 IU/mL) was added 2 h following 
compound treatment. After incubation with the compounds, 
medium was removed and cells were washed twice with PBS 
followed by adding 100  µl of 1× lysis buffer (0.2  M K2HPO4, 
0.2 M KH2PO4, Triton X-100, pH 7.6). 25 µl of lysate was assayed 
for luciferase activity by adding 50 µl of luciferase assay substrate 
(1 mM luciferin or luciferin salt, 3 mM ATP, and 15 mM MgSO4 
in 30 mM HEPES buffer, pH 7.8) followed by 10 s mixing and 
measuring 1  s bioluminescence using an Envision multilabel 
reader (Perkin Elmer).
qPcr analysis
qPCR was performed using the GoTaq qPCR Master Mix 
(Promega) according to manufacturer’s instructions. In 
short, a 25  µl reaction volume mix per sample was prepared 
containing 12.5  µl GoTaq qPCR Master Mix, 0.4  µM forward 
and reverse primer, and nuclease-free water. We used the 
Rotor-Gene Q qPCR machine of Qiagen with following PCR 
program: 95°C for 2 min, 40 cycli denaturation (95°C, 15 s) and 
annealing/extension (60°C, 30  s), and dissociation (60–95°C). 
Following primers were used: GAPDH FP (housekeeping 
gene HKG) GCTCTCTGCTCCTCCTGTTC; GAPDH RP 
(HKG) ACGACCAAATCCGTTGACTC; IL6 FP GACAG 
CCACTCACCTCTTCA; IL6 RP AGTGCCTCTTTGCTGC 
TTTC; GILZ FP TCAGACAGGACTGGAACTTCTCC; GILZ 
RP GCGTGAGAACACCCTGTTGA. Each sample was run 
in triplicate. The median value of the triplicates were taken to 
calculate the deltaCt-values using GAPDH as the normalization 
gene.
Western Blot analysis
Whole cell extracts contain multiple protease inhibitors (Complete 
Mini®, Roche) and Halt phosphatase inhibitor cocktail 
(Thermoscientific). Soluble protein extracts were obtained after 
three times freeze and thaw cycles and centrifugation at 16 g for 
15 min at 4°C. Samples were separated by sodium dodecyl sulfate-
polyacrylamidegel electrophoresis (SDS-PAGE) and transferred 
onto nitrocellulose membranes (Hybond C, Amersham) fol-
lowing standard protocols. After blocking, membranes were 
incubated overnight at 4°C with the primary antibodies: anti-GR 
(sc-8992, SantaCruz Biotechnology), anti-phospho-GR Ser211 
(4161, Cell Signalling) and anti-Actin (A3853, Sigma-Aldrich) 
followed by dye-conjugated secondary antibodies (LI-COR® 
Biosciences). Bound complexes were detected with the Odyssey® 
infrared imaging system (LI-COR®) and quantified by Image J 
software.
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Mass spectrometry analysis
Recombinant His6-MBP-mCaspase3 site-LBD-hGR was 
expressed in the Escherichia coli strain BL21codon + pICA2 that 
was transformed with the corresponding pLHM36LBD-hGR 
plasmid and in which expression was induced by Isopropyl 
β-D-1-thiogalactopyranoside (IPTG) under control of a 
pL-promotor. The transformed bacteria were grown in Luria 
Bertani medium supplemented with ampicillin (100  µg/ml) 
and kanamycin (50  µg/ml) overnight at 28°C before 1/100 
inoculation in 12 × 0.5 l provided with Luria Bertani medium 
supplemented with ampicillin (100  µg/ml) and 1% glycerol in 
a shaker incubator. The cells were grown to an optical density 
at AU 600 nm of 0.65, transferred to 20°C and expression was 
induced by addition of 1 mM IPTG overnight. Cells were then 
harvested and frozen at −20°C. The cell pellet after production 
was 60 g. After thawing, the cells were re-suspended at 3 ml/g 
in cold 20 mM Tris-HCl pH 7.4, 200 mM NaCl, 1 mM EDTA, 
1 tablet complete protease inhibitor cocktail from Roche/50 ml, 
and 10  mM β-mercaptoethanol. The cytoplasmic fraction was 
prepared by sonication of the cells on ice and isolated by cen-
trifugation at 18,000 × g for 30 min. All further purification steps 
were conducted at 4°C. The clear supernatant was applied to an 
amylase column (BioLabs, XK26  ×  20, 100  ml), equilibrated 
with 20 mM Tris–HCl pH 7.4, 200 mM NaCl, 1 mM EDTA, and 
10 mM β-mercaptoethanol. The column was eluted with 20 mM 
Tris–HCl pH 7.4, 200 mM NaCl, 1 mM EDTA, 10 mM maltose, 
and 10  mM β-mercaptoethanol. The elution fractions were 
analyzed on SDS-PAGE with Coomassie staining and western 
blot with anti-His6 detection (data not shown). Recombinant 
purified His-MBP-DEVD-GR-LBD fusion protein was dis-
solved at a concentration of 1 mg in 1.7 ml PBS buffer. To 128 µl 
of His-MBP-DEVD-LBD stock solution (75  µg, 1.05  nmol), 
3  µl (30  nmol) of Dex, Dex-Mes, UAMC-1158, UAMC-1159, 
GSK866, UAMC-1217, or UAMC-1218 stock solution (10 mM) 
or solvent (DMSO) was added.
Each aliquot was incubated 2  h at 37°C. Pierce Protein 
Desalting Spin Columns (max loading volume 120  µl) were 
equilibrated with 4  ×  400  µl 20  mM NH4HCO3 (pH 7.8) 
(15.8 mg/10 ml) (1,500 × g, 1 min). 120 µl of each sample was 
loaded onto a spin column and the flow-through was collected 
(1,500 × g, 2 min). Trypsin (5 µl of 20 mM stock solution) was 
added, and the samples were incubated 20  h at 37°C. Then, 
0.1% FA (formic acid) (41.5 µl) and 20 mM TCEP in 0.1% FA 
(18.5 µl, 5.7 mg TCEP/ml) were added [final volume = 185 µl, 
final concentration TCEP = 2 mM, 1 µg material/2.5 μl], and the 
samples were subjected to LC–MS/MS analysis.
The obtained peptide mixtures were introduced onto an 
LC–MS/MS system; the Ultimate 3000 RSLC nano (Dionex, 
Amsterdam, The Netherlands) in-line connected to an LTQ-
Orbitrap Velos (Thermo Fisher Scientific, Bremen, Germany). 
The sample mixture was loaded on a trapping column [made 
in-house, 100 µm internal diameter (I.D.) × 20 mm, 5 µm C18 
beads (Reprosil-HD, Dr. Maisch)]. After back flushing from the 
trapping column, the sample was loaded on a reverse-phase 
column [made in-house, 75 µm I.D. × 150 mm, 5 µm C18 beads 
(Reprosil-HD, Dr. Maisch)]. Peptides were loaded with solvent 
1 (0.1% trifluoroacetic acid, 2% acetonitrile) and were separated 
with a linear gradient from 2% solvent 1’ (0.1% formic acid) to 
55% solvent 2’ (0.1% formic acid and 80% acetonitrile) at a flow 
rate of 300 nl/min followed by a wash reaching 100% solvent 2’.
The mass spectrometer was operated in data-dependent 
mode, automatically switching between MS and MS/MS acqui-
sition for the 10 most abundant peaks in a given MS spectrum. 
In the LTQ-Orbitrap Velos, full scan MS spectra were acquired 
in the Orbitrap at a target value of 1E6 with a resolution of 
00060000. The 10 most intense ions were then isolated for 
fragmentation in the linear ion trap, with a dynamic exclusion 
of 30  s. Peptides were fragmented in HCD mode after filling 
the ion trap at a target value of 1E4 ion counts. From the MS/
MS data in each LC run Mascot Generic Files were created 
using the Distiller software (version 2.4.3.3, Matrix Science, 
www.matrixscience.com/distiller.html). While generating these 
peak lists, grouping of spectra was allowed in Distiller with a 
maximum intermediate retention time of 30 s and a maximum 
intermediate scan count of 5 was used where possible. Grouping 
was done with 0.005 Th precursor tolerances. A peak list was 
only generated when the MS/MS spectrum contained more 
than 10 peaks. There was no de-isotoping and the relative signal 
to noise limit was set at 2. These peak lists were then searched 
with the Mascot search engine [MatrixScience, http://www.
matrixscience.com (43)] using the Mascot Daemon interface 
(version 2.4.0, Matrix Science). Spectra were searched against the 
Swiss-Prot database (version 2012_11 of UniProtKB/Swiss-Prot 
protein database containing 538585 sequence entries of homo 
sapiens). Modifications of cysteine residues by GSK866, UAMC-
1217, -1218 or Dex, or Des-Mes were included in the respective 
searches as an additional variable. For the reference experiment 
with DMSO, the same search parameters were used as for the 
other test compounds. Mass tolerance on peptide precursor ions 
was set to 10 ppm (with Mascot’s C13 option set to 1), and on 
fragment ions to 0.5 Da. The peptide charge was set to 1+, 2+, 
3+ and instrument setting was put on ESI-TRAP. Enzyme was 
set to trypsin, allowing for one missed cleavage, also cleavage 
was allowed when arginine or lysine is followed by proline. Only 
peptides that were ranked one and scored above the threshold 
score, set at 99% confidence were withheld. Spectra identified 
as peptides modified with GSK866, UAMC-1158, -1159, -1217, 
-1218, or Dex were manually validated to ensure correct assign-
ment. All data management was done by ms_lims (44).
gr–coregulator interaction Profiling
Cofactor Interactions (coactivators and co-repressors) of recom-
binant glucocorticoid receptor ligand-binding domain (GR-LBD) 
complexed with different ligands Dex, GSK866, UAMC-1217, or 
UAMC-1218 were assessed by the Microarray Assay for Real-
time Coregulator-Nuclear real-time coregulator-nuclear recep-
tor Interaction (MARCoNI) as previously described (PamGene 
International B.V.) (16). In brief, all peptide array assays were 
performed on a Pamstation-12 at 20°C using two cycles per 
minute with 25 µl reaction mixture incubated for 40 min with 
Nuclear receptor buffer, 1 nM glutathione S-transferase (GST)-
tagged GR-LBD (A15668, Life Technologies, USA), 25  nM, 
Alexa Fluor 488-conjugated GST antibody (A-11131), 1 µl DTT 
(0.05 mM), and MQ water or vehicle (2% DMSO in MQ water) 
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with or without 1 μM receptor ligands Dex, GSK866, UAMC-
1217 or UAMC-1218 or solvent control (2% DMSO in water). 
Each pamchip array was blocked with 30 µl of blocking buffer 
(1% BSA/1× TBS, 0.01% Tween 20). Next, the reaction-ligand 
mixture was incubated for 80 cycles. To analyze the results of 
the MARCoNI assay, we used the Bionavigator image analysis 
software (Version 5.1, Pamgene International B.V.). The software 
analyzes the automatically identified spots and quantifies inten-
sities by calculating signal-minus background values and the 
receptor modulation index (MI) was subsequently calculated as 
the intensity of fluorescence change in presence of ligand over 
solvent control DMSO. All the images were obtained at cycles 
21, 41, 61, and 81, respectively, by a CCD camera-based optical 
system integrated in the PamStation-96 instrument (PamGene 
International B.V.). The statistical significance of ligand effects 
on GR-LBD were calculated by using a Student’s t-test by an 
inbuilt Bionavigator application.
Molecular Modeling
For covalent docking simulations in the GSK866 complexed 
GR-LBD (3E7C) structure, semi-flexible docking protocols 
were applied in Autodock Vina in which the binding residues of 
the target protein were kept flexible while the others were kept 
rigid (45). The Autodock Tools (GUI) program was used to add 
hydrogen atoms to the proteins and to merge non-polar contacts. 
Gasteiger charges were computed for the proteins. The grid box 
size was set at 20, 14, and 20  Å (x, y, and z), respectively. We 
optimized the total ligand–receptor interaction energy (ΔG) in 
kilocalorie per mole and its components by means of atomic level 
molecular mechanics simulations, based on a force field involv-
ing intermolecular van der Waals, electrostatic, and hydrogen 
bond interactions between the binding molecule and its recep-
tor. The docked bioactive conformation graphs of the different 
ligands were captured by the PYMOL program (version 1.5.04, 
Schrodinger, LLC). Next cooperative bonds were characterized 
which may stabilize ligand receptor binding of the non-steroidal 
ligand GSK866.
Molecular Dynamics simulation
The GSK866 complexed form of the GR-LBD (3E7C) was 
subjected to molecular dynamics (MD) simulations using the 
GROMACS 4.5.5 tool (46). The GROMOS96 43A1 force field 
was used to prepare the protein topology file. The topological 
structures of GR ligands UAMC-1217 and Dex were generated by 
the PRODRG server (47). The systems were solvated with simple 
point charge (SPC) water molecules in a cubic box with dimen-
sions 1 nm × 1 nm × 1 nm. Periodic boundary conditions were 
applied in all three (x, y, and z) directions to mimic the infinity of 
the system. At physiological pH conditions, the structures were 
found to be negatively charged. Hence, we added sodium ions 
(Na+) to make the system electrically neutral in the simulation 
box. The Berendsen temperature coupling method was applied to 
regulate the temperature inside the box. The particle mesh Ewald 
(PME) method (48) was used to treat the long-range electrostatic 
interactions. The pressure was maintained at 1 atm with an allowed 
compressibility range of 10−5 atm. The LINCS algorithm was used 
to constrain the bond lengths involving hydrogens, permitting a 
time step of 2 fs. Van der Waals and Coulomb interactions were 
truncated at 1.0 nm. The non-bonded pair list was updated every 
10 steps and conformations were stored every 0.5 ps. Finally, the 
systems were subjected to MD simulations for 100  ns each at 
300 K.
resUlTs
Molecular Modeling of cysteine reactive 
gsK866 analogs UaMc-1158, UaMc-
1159, UaMc-1217, and UaMc-1218
The crystal structure of the ligand-binding domain of the GR 
has been solved in complex with SEGRA compound GSK866 
(Figure 1), and this structure (pdb-code 3E7C) shows the loca-
tion of a GR-LBD cysteine residue (C643) in close proximity 
to the dichlorophenyl group of SEGRA compound GSK866 
(Figure  2A). Yellow spheres highlight the three-cysteine resi-
dues that are located in the vicinity of the ligand-binding pocket. 
The close presence of such a cysteine residue prompted us to 
design and synthesize different GSK866 analogs UAMC-1158, 
UAMC-1159, UAMC-1217, and UAMC-1218 (Figure  1) by 
introducing a reactive warhead into the structure, with the pos-
sibility of forming a covalent linkage between protein structure 
and ligand, upon binding (Figures 2B–E) (14).
segra gsK866 analogs UaMc-1217, 
UaMc-1218 but not UaMc-1158 and 
UaMc-1159 compounds elicit selective 
gr-Transactivation and nFκB-
Transrepression Properties
In a first series of experiments, we compared selective 
GR-transactivation and NFκB-transrepression effects of the 
SEGRA GSK866 and potential covalent-binding analogs 
UAMC-1158, UAMC-1159, UAMC-1217, and UAMC-1218 with 
non-covalent (Dex) and covalent binding (Dex-Mes) reference 
GR ligands, via GRE- and NFκB-dependent luciferase assays 
in stable transfected reporter gene cell lines (8, 35). GRE-luc 
reporter gene cells were exposed for 6 h to the different GSK866 
analogs and reference compounds Dex and Dex-Mes in a con-
centration range of 10−6–10−10 M (Figure 3). In line with previous 
reports, Dex-Mes shows weaker dose-dependent GR-dependent 
transactivation than Dex (Figures 3A,B) (24). Analogous to the 
covalent GR binding ligand Dex-Mes, adding covalent warheads 
to GSK866 also significantly reduces the ligand transactivation 
properties, when compared to the strong GR agonistic activities 
of GSK866, whereas compounds UAMC-1158 and UAMC-1159 
completely fail to elicit any GR transactivation at any dose tested 
(Figures 3C–E). Interestingly, whereas 10 nM of GSK866 dem-
onstrates significant GR transactivation, similar concentrations 
of UAMC-1217 and UAMC-1218 show significantly reduced 
GR transactivation to levels below transactivation observed with 
FigUre 1 | Chemical structures. Chemical structures of selective glucocorticoid receptor agonist GSK866 and synthetic analogs UAMC-1158, UAMC-1159, 
UAMC-1217, and UAMC-1218.
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10 nM of Dex (Figures 3F,G). These results correspond with the 
approx. 5-fold lower GR-LBD affinity for ligands UAMC-1217 
(IC50 22 nM), UAMC-1218 (IC50 34 nM) versus GSK866 (IC50 
4.6  nM), as demonstrated in ligand displacement assays with 
radiolabeled Dex (14) (Table 1).
Upon further investigation of ligand-specific anti-
inflammatory effects in NFκB-luciferase reporter gene assays, 
we observed dose-dependent NFκB-transrepression effects 
of GSK866 and the analogs UAMC-1217 and UAMC-1218, 
whereas UAMC-1158 and UAMC-1159 are completely ineffec-
tive (Figures  3D–G). Interestingly, UAMC-1217 and UAMC-
1218 demonstrate stronger anti-inflammatory NFκB repression 
effects than Dex-Mes and Dex at 10  nM concentration. For 
example, 10  nM UAMC-1217 and UAMC-1218 both reduce 
TNF-induced NFκB reporter gene activity approximately 
95% (UAMC-1217), 95% (UAMC-1218), whereas Dex-Mes 
and Dex only show 40–45% inhibition (Figures  3A–F). This, 
in combination with weaker GR transactivation properties 
at 10  nM concentrations as compared to Dex, skews the GR 
towards more selective GR transrepression properties. Similar 
to the lack of GR transactivation, no transrepression activity 
could be detected for UAMC-1158 and UAMC-1159 ligands. 
The latter suggests that UAMC-1158 and UAMC-1159 analogs 
fail to regulate GR-dependent reporter gene expression, in line 
with results obtained in cell-based ligand-binding competi-
tion assays which failed to show displacement of radiolabeled 
Dex upon treatment with UAMC-1158 and UAMC-1159 (14) 
(Table 1).
FigUre 2 | Molecular 3D modeling of cysteine reactive GSK866 analogs UAMC-1158, UAMC-1159, UAMC-1217, and UAMC-1218. Molecular 3D modeling of 
SEGRA GSK866 (a) and synthetic analogs UAMC-1158 (B), UAMC-1159 (c), UAMC-1217 (D), and UAMC-1218 (e) in the glucocorticoid receptor ligand-binding 
domain crystal structure 3E7C. Proximal cysteine residues C622, C643, and C736 are represented as yellow balls.
7
Chirumamilla et al. SEGRA Properties of Electrophilic GSK866 Analogs
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1324
segra gsK866 analog UaMc-1217 
Demonstrates anti-inflammatory il6 gene 
Transcription concomitantly with reduced 
gilZ/Tsc22D3 Transcription levels
To confirm GR- and NFκB-specific reporter gene results at the 
level of endogenous target gene expression in HaCat cells, we 
next compared effects of 6 h treatment of Dex and UAMC-1217 
on mRNA transcription levels of the GR target gene GC-induced 
leucine zipper (GILZ)/TSC22D3 as well as the inflammatory and 
TNF-inducible NFκB target gene interleukin 6 (IL6) (Figure 4). 
In line with the GR- and NFκB-specific reportergene results, we 
could confirm anti-inflammatory effects of UAMC-1217 in the 
nanomolar range, with reduced transactivation effects at the level 
of GILZ/TSC22D3 gene expression.
segra gsK866 analogs UaMc-1217, 
UaMc-1218 Trigger gr ser211 
Phosphorylation
It is well accepted that hormone-dependent phosphorylation 
of GR at Ser211 is a marker for transcriptional GR activation 
(49, 50). Therefore, GR-luciferase reporter cells were exposed for 
6 h to Dex, Dex-Mes, GSK866, and SEGRA analogs UAMC-1217 
and UAMC-1218 to test their transcriptional GR activation. 
Total cell lysates were analyzed for expression levels of GR, 
FigUre 3 | Selective glucocorticoid receptor agonist GSK866 analogs UAMC-1217, UAMC-1218 but not UAMC-1158 and UAMC-1159 elicit selective 
glucocorticoid receptor-transactivation and NFκB-transrepression properties. Glucocorticoid response element (GRE)- and NFκB-luciferase-dependent reporter 
gene assays were performed in L929sA and HaCat reporter cells which were stably transfected with, respectively, p(NFκB)3-50luc or p(GRE)2-50-luc constructs. For 
p(GRE)2-50-luc reporter assays, cells were solvent-treated or induced with different concentrations of Dex (a), Dex-mesylate (Dex-Mes) (a), SEGRA GSK866 (c) or 
analogs UAMC-1158 (D), UAMC-1159 (e), UAMC-1217 (F), and UAMC-1218 (g) as indicated for a total exposure time of 6 h, whereas cells were cotreated for 
TNF (2,500 IU/ml) in the last 4 h for p(NFkB)3-50luc reporter assays (B–g). Corresponding lysates were assayed for luciferase activities and normalized for protein 
content as described in the Section “Materials and Methods.” Promoter activities are expressed as relative induction factor (± standard deviation) i.e., the ratio of 
expression levels recorded either at induced and non-induced conditions, with the latter taken to be 1.
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FigUre 4 | Selective glucocorticoid receptor agonist GSK866 analog 
UAMC-1217 elicits glucocorticoid receptor selective downstream anti-
inflammatory effects at endogenous target genes. (a) QPCR assays was 
performed against the GR target gene GILZ/TSC22D3 in HaCat cells treated 
for 6 h with different concentrations 10, 100 or 1,000 nM Dex or UAMC-
1217. Bar graph plot represents the relative mRNA levels of GILZ/TSC22D3 
upon Dex or UAMC-1217 treatment. (B) QPCR assays was performed 
against the TNF-inducible inflammatory gene interleukin-6 (IL6) in HaCat cells 
treated for 6 h with different concentrations 10, 100, or 1,000 nM Dex or 
UAMC-1217 either or not, cotreated for the last 4 h with TNF (2,500 IU/ml) as 
indicated in panel (B). All the qPCR assays have been normalized to the 
GAPDH mRNA housekeeping gene. Bar graphs represent relative mRNA 
(mean ± SD) levels of three replicates. Significant mean differences versus 
control setups panel (a) or TNF treated setup panel (B) are marked as *** 
(P < 0.001), **(P < 0.01), * (P < 0.05) and were determined by one-way 
ANOVA (Dunnetts Posttest).
TaBle 1 | Cell-based GR ligand-binding competition assay with 1.5 nM 
[3H]-dexamethasone upon competition treatment with 1 µM of the different 
ligands indicated (14).
ligand % inhibition of gr ligand binding ic50 (nM) Ki (nM)
Dex 100
Dex-mesylate 99 7.3 3.7
GSK866 100 4.6 2.3
1158 −2
1159 −12
1217 92 22 11
1218 96 34 17
% inhibition of GR radioligand binding, IC50 (nM) and Ki (nM) are indicated.
Gray shade indicates values not applicable.
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phosphoGR-Ser211, and actin. From Figures  5A,B, it is clear 
that SEGRA compound GSK866 and its analogs UAMC-1217 
and UAMC-1218 enhance the Ser211 phosphorylation at 6 h, in 
analogy to Dex. Furthermore, concentration-dependent increase 
of GR Ser211 phosphorylation can be detected upon Dex or 
UAMC-1217 treatment (Figures 5C,D). By contrast, the inactive 
compound UAMC-1158 failed to show any change in GR phos-
phorylation status upon induction (Figure S2 in Supplementary 
Material).
segra gsK866 analogs UaMc-1217, 
UaMc-1218, but not UaMc-1158 and 
UaMc-1159 Trigger nuclear gr 
Translocation
Next, we investigated whether in analogy to Dex and Dex-Mes, 
SEGRA compound GSK866 and its analogs UAMC-1158, UAMC-
1159, UAMC-1217, and UAMC-1218 are able to trigger nuclear 
translocation of GR in A549 cells, using an immunofluorescence 
approach, allowing automated image quantification of GR trans-
location. Serum starved cells were treated for 30 min with mock 
control (solvent), Dex, Dex-Mes, SEGRA GSK866 and analogs 
UAMC-1158, UAMC-1159, UAMC-1217, or UAMC-1218. GR 
translocation was evaluated by indirect immunofluorescence 
using an anti-hGR antibody as primary antibody and a FITC 
labeled secondary antibody. Nuclei were stained by DAPI. Nuclear 
GR translocation was evaluated by overlapping DAPI staining 
with the GR FITC signal. As can be observed (Figure 6A), besides 
Dex, also Dex-Mes, GSK866, and its analogs UAMC-1217 and 
UAMC-1218 induce (partial) translocation of GR from the cytosol 
to the nucleus, whereas UAMC-1158 and UAMC-1159 are com-
pletely ineffective. Similar conclusions can be drawn from the bar 
graph, which summarizes relative intensities of GR translocation 
(based on nuclear-to-cytoplasm signal intensity ratio) following 
standardized image quantification (see Materials and Methods) of 
the different immunofluorescence pictures (Figure 6B).
Dex-Mes and segra compounds  
UaMc-1217 and UaMc-1218 but not 
gsK866 or Dex Bind covalently to  
gr-lBD-specific cysteines
Next, we further investigated whether the cysteine reactive 
warheads of the active SEGRA GSK866 analogs UAMC-1217 
and UAMC-1218 promote covalent ligand binding to GR-LBD 
in analogy to Dex-Mes. Ligand-specific interactions with 
cysteine-containing peptides of GR-LBD were identified by 
mass spectrometry analysis of trypsin-digested recombinant 
GR-LBD following incubation with SEGRA compound GSK866, 
or its analogs UMAC-1217 and UAMC-1218, and reference 
compounds Dex and Dex-Mes. For all samples, good peptide 
coverage of the GR-LBD protein could be observed (>85%), 
and all cysteine-containing peptides were identified following 
trypsin digestion. Upon screening of all possible trypsin cleaved 
FigUre 5 | Selective glucocorticoid receptor agonist GSK866 and its analogs UAMC-1217, UAMC-1218 trigger glucocorticoid receptor (GR) Ser211 
phosphorylation. (a) Western detection of expression levels of Actin, GR, and GR Ser S211 phosphorylation in HaCat cells following 6 h treatment with 1 µM Dex, 
UAMC-1217, UAMC-1218, or GSK866. (B) Bar plot representation of Western blot intensities of Actin, GR, and GR Ser S211 phosphorylation observed in panel A, 
as quantified by Image J. (c) Western detection of expression levels of Actin, GR expression, and Ser S211 phosphorylation in HaCat cells following 6 h treatment 
with, respectively, 10, 100, or 1,000 nM Dex or UAMC-1217. (D) Bar plot representation of Western blot intensities of Actin, GR, and GR Ser S211 phosphorylation 
observed in panel (c), as quantified by free Image J software.
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GR-LBD peptides for mass shifts of the different ligands, covalent 
binding to GR-LBD could be detected at cysteine C622 for Dex-
Mes. Along the same line, covalent binding of GSK866 analogs 
UAMC-1217 and UAMC-1218 to Cys-622 GR-LBD could also 
be demonstrated (Table  2). By contrast, no covalent peptide 
interactions could be demonstrated for Dex, nor the SEGRA 
GSK866 ligand, as expected, since both lack covalent warheads 
for covalent interactions. In contrast to previous reports, which 
identified cysteine 656 as the major target site for covalent bind-
ing of Dex-Mes in rat GR, mass spectrometric analysis identi-
fied cysteine C622 as the most reactive amino acid for covalent 
interaction with Dex-Mes in human recombinant GR (51). Of 
special note, Crystal structure of the human GR-LBD and other 
human recombinant GR often does not contain the evolution-
ary conserved Cys655 (corresponding to rat Cys 656), since this 
amino acid was mutated to glycine to optimize soluble expres-
sion and to allow purification of the GR-LBD (52). As such, the 
current experiments cannot exclude, nor confirm, that Dex-Mes 
can bind covalently to additional cysteine residues in full-length 
wild-type hGR in a physiological cellular context. With respect 
to covalent-binding modes of GSK866 analogs UAMC-1217 
and UAMC-1218, mass spectrometry analysis also identified 
the more solvent exposed cysteine C622 but not the structurally 
predicted proximal C-643 as the most reactive amino acid for 
covalent ligand interaction to the GR-LBD. The latter suggests 
more favorable reaction kinetics for the flexible cysteine C622 
than the structural restrained cysteine C643 in covalent ligand 
binding. Altogether, we confirmed cysteine-dependent covalent 
binding of Dex-Mes and covalent warhead containing SEGRA 
compounds UAMC-1217 and UAMC-1218 to GR-LBD.
TaBle 2 | Dex-mesylate (Dex-Mes) and selective glucocorticoid receptor agonist 
(SEGRA) compounds 1217 and 1218 but not GSK866 or Dex covalently bind 
glucocorticoid receptor ligand-binding domain (GR-LBD)-specific cysteines.
sample Modifications
Ctrl –
Dex –
Dex-Mes Peptide 615–633 → C622
GSK866 –
1217 Peptide 615–633 → C622
1218 Peptide 615–633 → C622
MassspecMass spectrometry-based identification of GR-LBD cysteine-containing 
peptides which bind covalently to SEGRAs GSK866, 1217, or 1218. The position of 
the LBD peptide in hGR is indicated by the residue numbers of the first and last amino 
acid of the peptide (according to the SwissProt database). The modified residue is 
described by the official amino acid acronym and its position in hGR.
FigUre 6 | Selective glucocorticoid receptor agonist GSK866 analogs 
UAMC-1217, UAMC-1218, but not UAMC-1158 and UAMC-1159 trigger 
nuclear glucocorticoid receptor (GR) translocation. (a) Serum starved A549 
cells were left solvent treated or treated for 30 min with 1 µM Dex, 
Dex-mesylate (Dex-Mes), GSK866, UAMC-1158, UAMC-1159, UAMC-1217, 
or UAMC-1218. GR translocation was evaluated by immunofluorescence 
whereas nuclei were stained by DAPI dye. Magnification is at 100×. White 
scalebars represent 20 µM. (B) Automated image quantification of GR 
translocation of three replicate immunofluorescence images of the different 
experimental setups.
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conformational cofactor Binding Profiling 
of the gr-lBD reveals Quantitative 
Differences in agonist conformation  
by Dex, gsK866, UaMc-1217,  
and UaMc-1218
To further characterize the GR-LBD conformation upon 
binding of the different active GSK866 analogs, we performed 
peptide array-based cofactor profiling to fingerprint 53 LxxLL-
specific cofactor interactions with recombinant GR-LBD in 
the presence of the GR agonist Dex, SEGRA GSK866, or the 
analogs UAMC-1217 and UAMC-1218 (16). By comparing 
the corresponding peptide interaction profile of the differ-
ent ligands, to the profiles obtained with Dex agonist bound 
GR-LBD, it is possible to fingerprint the relative agonistic con-
formational changes. As can be observed from (Figure  7A), 
the cofactor profiles of GSK866 and analogs UAMC-1217 and 
UAMC-1218 promote a similar agonistic cofactor binding 
profile as Dex treatment. However, whereas some coactivator 
interactions show similar intensities as Dex (for example, 
NCOA1_1421_1441), other coactivator interactions (for 
example, NCOA6_875_897) show significant quantitative 
differences, suggesting subtle ligand-specific conformational 
differences underlying its SEGRA properties (Figures 7A,B).
Based on our semi-flexible docking models, we found that 
spatial occupation of GSK866, and analogs UAMC-1217 or 
UAMC-1218 in the GR-LBD differ from the binding mode of 
Dex in the GR-LBD (Figures S3A–E in Supplementary Material). 
In addition to 4 intermolecular H bonds in the GR-LBD pocket 
(LEU 563, ASN 564A, GLN 570A, and GLN 642A), GSK866 
also forms non-H bond interactions (MET 560A, PHN 623A, 
GLN 642, and TYR 735) (Figure S3A in Supplementary 
Material). Upon molecular docking of UAMC-1217 and 
UAMC-1218 in the GSK866 bound GR-LBD crystal structure 
(3E7C), stable binding energies of −10.6 and −10.3  kcal/mol 
were obtained, respectively. The pyrazole group and dichlo-
rophenyl ring of UAMC-1217 forms π bonds with GLN 642 
and MET-604, whereas MET604, PHE623, ASN564, LEU563, 
LEU608, and GLN642 residues constitute strong hydrophobic 
interactions (Figure S3C in Supplementary Material). Hence, 
as expected, the interaction profile of UAMC-1217 (Figure S3C 
in Supplementary Material), more closely resembles GSK866 
FigUre 7 | Conformational cofactor binding profiling of the glucocorticoid receptor ligand-binding domain reveals quantitative differences in GR agonist 
conformation by Dex, or SEGRA compounds GSK866, UAMC-1217, and UAMC-1218. (a) Compound-induced log-fold modulation of GR binding [modulation 
Index (MI)] to coregulator motifs. Red indicates enhancement of binding, while blue represents peptide displacement. (Dis-) similarity between modulation profiles of 
compounds (rows) and motifs (columns) is visualized by hierarchical clustering (Euclidean distance, Ward’s clustering). (B) Bar plot representation of significantly 
increased coactivator peptide binding profiles. Bar height represents binding (mean ± SD in Arbitrary Units fluorescence) of three technical replicates (arrays) per 
condition. The color of each bar indicates MI (versus GR binding in the presence of solvent only, DMSO, first bar). Significance of the modulation is indicated by 
asterisks (*P < 0.05; **P < 0.01; ***P < 0.001).
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(Figure S3A in Supplementary Material) than Dex binding to 
GR-LBD (Figure S3E in Supplementary Material).
Molecular Dynamic simulations of  
gr-lBD Bound to the novel segra 
compound UaMc-1217
To predict transient dynamic changes in GR-LBD structure 
upon binding to an active SEGRA analog UAMC-1217 we 
performed molecular dynamic (MD) simulations. Due to 
computational time limitations, the MD simulations could 
not be repeated for all ligands included in our study. As input 
for the MD simulations we selected the structural model of 
SEGRA compound UAMC-1217, bound to the GR from the 
crystallized 3E7C protein-ligand complex, with an optimized 
binding energy of −10.6 kcal/mol (Figure S3 in Supplementary 
Material). In order to compare dynamic conformational vari-
ations of the GR-LBD (3E7C) upon interaction with SEGRA 
TaBle 3 | Average values of root mean square deviation (RMSD), root mean 
square fluctuation (RMSF), radius of gyration (Rg), solvent accessible surface 
area (SASA), number of hydrogen bonds (NH-bonds), and NH-bonds between 
protein and Drug of 3E7C-apo, 3E7C-UAMC-1217 and 3E7C-Dex.
Parameters 3e7c-apo 3e7c-1217 3e7c-Dex
RMSD (nm) 0.34 ± 0.04 0.34 ± 0.07 0.35 ± 0.05
RMSF (nm) 0.15 ± 0.10 0.14 ± 0.13 0.11 ± 0.10
Rg (nm) 1.76 ± 0.01 1.78 ± 0.01 1.76 ± 0.01
SASA (nm2) 70.54 ± 2.15 72.23 ± 2.16 72.25 ± 2.04
NH-bonds 194.86 ± 6.99 194.61 ± 7.33 198.67 ± 11.05
NH-bonds (protein-drug) – 2.06 ± 0.80 1.95 ± 0.67
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UAMC-1217, we studied the root mean square deviation 
(RMSD), root mean square fluctuation (RMSF), radius of 
gyration (Rg), solvent accessible surface area (SASA), num-
ber of hydrogen bonds (H-bonds), and secondary structure 
analysis (DSSP) between the apo GR-LBD (3E7C-Apo) form 
and GR-LBD form bound to UAMC-1217 (3E7C-1217) or Dex 
(3E7C-Dex) ligand. From the start to ~35,000 ps, the RMSD 
of the backbone atoms of the 3E7C–1217 complex structure 
shows significant differences as compared to 3E7C-apo, 
during the simulation (Figure  8A). After the time period of 
~35,000,000 ps, the RMSD of both complex structures (3E7C-
1217 and 3E7C-Dex) and 3E7C-apo show a similar profile till 
the end of the simulation. It is clear that the RMSD of the back-
bone atoms of both the 3E7C-1217 and 3E7C-Dex complex 
and 3E7C-apo reach a stable conformation. The average RMSD 
values of the 3E7C (apo), 3E7C-1217 and 3E7C-Dex complex 
structures are presented in Table 3.
To analyze the flexibility behavior of the 3E7C protein upon 
binding of UAMC-1217 and Dex, we calculated the RMSF of Cα 
atoms of each residue. In Figure 8B, a minor fluctuation can be 
observed in 610–660 region (helix 5) and 700–720 region (loop 
region 11), which indicates that UAMC-1217 and Dex binding 
to the GR-LBD complex elicit subtle differential effects in the 
molecular dynamics as compared to the Apo form. Furthermore, 
the average RMSF values of the both complex structures are 
somewhat lower than 3E7C-Apo structure (Table  3). This 
is further supported by the surface and geometry analysis of 
3E7C upon binding of UAMC-1217 or Dex, by analyzing the Rg 
and SASA (Figures 8C,D). In both the Rg and SASA plot, the 
3E7C-1217 complex shows a slightly larger structural deviation 
between ~16,000 and 60,000 ps than the 3E7C-Apo and 3E7C-
Dex structures. Overall, the average values of Rg and SASA 
(Table 3) show a comparable binding pattern for UAMC-1217 
and Dex GR-LBD complex structures. To understand the pat-
tern recognition of hydrogen-bonded and geometrical features 
in the secondary structures before and after the complex, we 
used NH-bond analysis and the DSSP program (53). The most 
significant changes in the residue position of 600–630 (indicated 
as 75–110 in Figure 8E) and 700–720 (indicated as 174–194 in 
Figure 8E) show a higher helical content in the both 3E7C-1217 
and the 3E7C-Dex complex structures. Altogether, these results 
suggest that the docked complex structures (3E7C-1217 and 
3E7C-Dex) are stable over time. To confirm this, we performed 
intermolecular NH-bond analysis. Due to the helical content, the 
ligand bond GR-LBD structures show more H-bonds than the 
3E7C-apo structure (Figure 8F). Furthermore, we also observed 
intramolecular hydrogen bonds between the protein and drug 
during the simulation time period (Figure  8G). It clearly 
demonstrates that the 3E7C-1217 complex shows very similar 
ligand-binding dynamics as the 3E7C-Dex complex. Besides, 
the 3E7C-1217 complex shows a slightly higher number of 
intramolecular H-bonds than the 3E7C-Dex complex. Overall, 
MD simulation analysis collectively suggest that, besides subtle 
transient dynamic changes, average GR-LBD conformations 
upon binding to UAMC-1217 or Dex show a similar way of 
ligand-binding dynamics which leads to a stable interaction 
between the protein and ligand molecule.
DiscUssiOn
Topical GCs are the most commonly prescribed anti-inflammatory 
agents in management of many cutaneous inflammatory 
diseases and the preferred mode of application is by topical 
administration of a corticoid agonist. However, long-term use 
of GCs is associated with many side effects such as skin atrophy, 
systemic toxicity, and rebound effects after discontinuation of 
the treatment. Current therapeutic regimens available at the 
market for topical applications include steroid analogs, such 
as clobetasol, mometasone (Elocom), and bethamethasone. 
Meanwhile, also non-steroidal SEGRAcompounds have been 
designed with more selective anti-inflammatory properties 
and less adverse side effects, such as CpdA (38), ZK245186 
(54), and GSK866 (15). The aim of the current study was to 
evaluate potential SEGRA properties of novel GSK866 analogs 
with covalent warheads for more selective anti-inflammatory 
properties. The reactive anchor group in the ligand acts as an 
electron-deficient Michael acceptor to target nucleophilic thiol 
rich cysteines in the ligand-binding domain of GR. Such an 
approach is conceptually attractive, since having a long-lasting 
covalent linkage between the ligand and the GR might poten-
tially prolong the therapeutic effect and reduce adverse systemic 
side effects, since smaller doses of the drug can be applied. Novel 
SEGRA GSK866 analogs with potential cysteine C643 reactive 
covalent warheads were designed in silico and synthesized (14) 
for further molecular characterization of SEGRA properties in 
cell-based assays.
Dose–response studies of the different GSK866 analogs in 
GRE- and NFκB-dependent reporter gene studies revealed 
consistent anti-inflammatory but reduced GR transactivation 
effects for GSK866 analogs UAMC-1217 and UAMC-1218 at nM 
concentrations, whereas analogs UAMC-1158 and UAMC-1159 
were found to be completely inactive at μM concentrations. 
Similar results were obtained at the endogenous gene level, 
which revealed dose-dependent immunosuppressive effects of 
UAMC-1217 and Dex, which dose-dependently reverse TNF 
induced IL6 gene expression, whereas maximal GR-dependent 
GILZ/TSC22D3 gene transcription is reduced for UAMC-1217 
in comparison to Dex treatment.
Along the same line, GR Ser211 phosphorylation and nuclear 
GR translocation could be observed upon cellular treatment with 
FigUre 8 | Molecular dynamic simulations of glucocorticoid receptor ligand-binding domain bound to the novel SEGRA compound UAMC-1217. (a) RMSD of 
3E7C-apo, 3E7C-1217, and 3E7C-Dex versus time at 300 K. (B) RMSF of the backbone of C-alpha. (c) Radius of gyration of C-alpha atoms. (D) Solvent-
accessible surface area of 3E7C-apo, 3E7C-1217, and 3E7C-Dex versus time at 300 K. (e) Time evolution of the secondary structural elements of 3E7C-apo, 
3E7C-1217, and 3E7C-Dex at 300 K (DSSP classification). (F) NH-bond of 3E7C-apo, 3E7C-1217, and 3E7C-Dex versus time at 300 K. (g) Average number of 
intramolecular hydrogen bonds between protein and drug.
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GSK866 analogs UAMC-1217 and UAMC-1218, whereas no 
effects could be observed upon treatment with UAMC-1158 or 
UAMC-1159. These results are in line with [3H]-dexamethasone 
radioligand binding competition assays (Table  1) (14), which 
show near complete displacement of GR ligand binding with the 
SEGRA GSK866, and synthetic analogs UAMC-1217 and UAMC-
1218, whereas compounds UAMC-1158 and UAMC-1159 are 
completely inactive. As such, it cannot be excluded that cellular 
metabolization of UAMC-1158 or UAMC-1159 compounds or 
their promiscuous reactivity may prevent GR specific ligand 
activity.
Furthermore, SEGRA properties of UAMC-1217 and 
UAMC-1218 were further supported by conformational cofactor 
binding profiling experiments of recombinant GR-LBD with the 
MARCoNI peptide array (16, 55). Whereas most coactivator 
interactions mimicked ligand-binding effects of the full agonist 
Dex, we observed a subtle conformational difference of the 
GR-LBD with a few coactivator peptides, which may finetune 
SEGRA properties. However, one limitation of our approach 
is that only ligand induced allosteric GR-LBD conformational 
changes are evaluated in the cofactor profiling, whereas additional 
GR-LBD-independent or allosteric control mechanisms induced 
by the DNA-responsive element are not taken into account, 
which may also contribute in DNA-context-dependent SEGRA 
properties (56).
Finally, molecular dynamic (MD) simulations were 
performed to detect transient dynamic changes in GR-LBD 
structure upon binding to UAMC-1217 as compared to a Dex 
liganded or unliganded (Apo) GR-LBD E7C crystal structure. 
Due to computational limitations, molecular dynamic simula-
tions were restricted to compound UAMC-1217 which was 
predicted to be the SEGRA GSK866 analog with the most 
stable GR-LBD binding energy (−10.5 kcal/mol, according to 
Autodock Vina). Interestingly, RMSD and RMSF simulations 
revealed transient (from start to ~35,000  ps) conformational 
differences with Dex binding to GR-LBD across helix 5 at posi-
tions 600–630, including the cysteine C622 which was identi-
fied as a covalent target for 1217 in mass spectrometric analysis. 
Later than 35,000 ps, simulation predicts disappearance of the 
conformational differences and both 1217 or Dex complexed 
GR-LBD conformations evolve toward similar stable struc-
tures. Remarkably, although molecular modeling identified 
cysteines C643 and C736 in the GR-LBD as the most favorable 
proximal targets for covalent binding of SEGRA compounds 
UAMC-1217 and UAMC-1218, mass spectrometry analysis 
identified the solvent exposed C622 as the most reactive site for 
covalent binding by UAMC-1217, UAMC-1218, and Dex-Mes. 
However, whether 1217 targets additional cysteine residues 
present in full-length GR besides GR-LBD C622 needs further 
investigation.
In conclusion, by combining various molecular cellular assays, 
we demonstrate that GSK866 analogs UAMC-1217 and UAMC-
1218 hold promise as a novel class of covalent-binding SEGRA 
ligands for treatment of inflammatory disorders. Development 
of therapeutic SEGRA agonists with stronger anti-inflammatory 
potential with less side effects in cutaneous and ocular inflam-
matory diseases is promising area for therapeutic intervention 
(57–62). In this respect, future investigations will be required 
to translate preclinical in vitro results of covalent SEGRA com-
pounds UAMC-1217 and UAMC-1218 into clinical (topical) 
applications for treatment of long-lasting skin and/or ocular 
inflammatory disorders.
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FigUre s1 | Automated image analysis of nuclear glucocorticoid receptor (GR) 
translocation by determining the ratio nuclear region of interest versus 
cytoplasmic region of interest (see Materials and Methods).
FigUre s2 | (a) Western detection of glucocorticoid receptor (GR) expression 
and Ser S211 phosphorylation levels in p(GRE)2-50-luc reporter Hacat cells 
following 4 or 24 h treatment with 1 µM Dex, GSK866, UAMC-1158, 
UAMC-1217, or UAMC-1218. (B) Western detection of GR expression and 
Ser211 phosphorylation levels in p(GRE)2-50-luc reporter cells following 4 h 
solvent treatment, or exposure to 1 µM Dex, Dex-mesylate (Dex-Mes), or 
UAMC-1217.
FigUre s3 | Molecular 2D–3D modeling of selective glucocorticoid receptor 
agonist GSK866 (a) and synthetic analogs UAMC-1158 (B), UAMC-1159 (c), 
UAMC-1217 (D), UAMC-1218 (e) in the glucocorticoid receptor ligand-binding 
domain crystal structure 3E7C.
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